468 related articles for article (PubMed ID: 29797220)
1. Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials.
Wang Y; Zhang H; Shen W; He P; Zhou Z
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1751-1768. PubMed ID: 29797220
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis.
Zhang X; Zhang G; Wang J; Bi J
Front Endocrinol (Lausanne); 2023; 14():1131033. PubMed ID: 36843606
[TBL] [Abstract][Full Text] [Related]
3. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
Loblaw DA; Walker-Dilks C; Winquist E; Hotte SJ;
Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
[TBL] [Abstract][Full Text] [Related]
4. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.
Niazi M; Jahangir A; Sahra S; Sattar S; Asti D; Bershadskiy A
Oncology (Williston Park); 2021 Nov; 35(11):708-715. PubMed ID: 35088974
[TBL] [Abstract][Full Text] [Related]
6. First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials.
Poorthuis MHF; Vernooij RWM; van Moorselaar RJA; de Reijke TM
BJU Int; 2017 Jun; 119(6):831-845. PubMed ID: 28063195
[TBL] [Abstract][Full Text] [Related]
7. Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
Wang X; Hui Y; Wang S; Hu X; Yu X; Wang W; Zhang X; Liu L
J Pharm Pharm Sci; 2020; 23():451-461. PubMed ID: 33217255
[TBL] [Abstract][Full Text] [Related]
8. Therapy Update for Metastatic Castration-Resistant Prostate Cancer.
Dinh JA; Baker D; Chahal M
Consult Pharm; 2016; 31(10):581-592. PubMed ID: 27725068
[TBL] [Abstract][Full Text] [Related]
9. Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis.
Guan Y; Xiong H; Feng Y; Liao G; Tong T; Pang J
Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):220-231. PubMed ID: 32034294
[TBL] [Abstract][Full Text] [Related]
10. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials.
Roviello G; Sigala S; Sandhu S; Bonetta A; Cappelletti MR; Zanotti L; Bottini A; Sternberg CN; Fox SB; Generali D
Eur J Cancer; 2016 Jul; 61():111-21. PubMed ID: 27162152
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer.
McCool R; Fleetwood K; Glanville J; Arber M; Goodall H; Naidoo S
Value Health; 2018 Oct; 21(10):1259-1268. PubMed ID: 30314628
[TBL] [Abstract][Full Text] [Related]
12. Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses.
Lee HY; Chen HL; Teoh JY; Chen TC; Hao SY; Tsai HY; Huang WH; Juan YS; Cheng HM; Chang HM
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):244-252. PubMed ID: 32860011
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X
Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis.
Song P; Huang C; Wang Y
Int J Surg; 2018 Aug; 56():133-140. PubMed ID: 29906643
[TBL] [Abstract][Full Text] [Related]
15. Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
Sternberg C; Armstrong A; Pili R; Ng S; Huddart R; Agarwal N; Khvorostenko D; Lyulko O; Brize A; Vogelzang N; Delva R; Harza M; Thanos A; James N; Werbrouck P; Bögemann M; Hutson T; Milecki P; Chowdhury S; Gallardo E; Schwartsmann G; Pouget JC; Baton F; Nederman T; Tuvesson H; Carducci M
J Clin Oncol; 2016 Aug; 34(22):2636-43. PubMed ID: 27298414
[TBL] [Abstract][Full Text] [Related]
16. Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis.
Fallara G; Belladelli F; Robesti D; Raggi D; Nocera L; Marandino L; Galsky MD; Montorsi F; Malavaud B; Ploussard G; Necchi A; Martini A
Crit Rev Oncol Hematol; 2022 Nov; 179():103801. PubMed ID: 36031173
[TBL] [Abstract][Full Text] [Related]
17. What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis.
Sun G; Zhang X; Chen J; Liao B; Liu Z; Zhao J; Gao AC; Yang Y; Shu K; Liu J; Zhao P; Shen P; Zeng H
Urol Oncol; 2018 Dec; 36(12):505-517. PubMed ID: 30316578
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
Wei Z; Chen C; Li B; Li Y; Gu H
Front Oncol; 2021; 11():732599. PubMed ID: 34513709
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer.
Lorente D; Llacer C; Lozano R; de Velasco G; Romero-Laorden N; Rodrigo M; Sánchez-Iglesias Á; di Capua C; Castro E; Ferrer C; Sánchez-Hernández A; Olmos D
Eur Urol; 2021 Nov; 80(5):641-649. PubMed ID: 34373138
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer: A systematic review and meta-analysis of randomized controlled trials.
Zheng X; Zhao X; Xu H; Han X; Xu H; Dong X; Peng R; Yang L; Wei Q; Ai J
Medicine (Baltimore); 2019 Nov; 98(44):e17748. PubMed ID: 31689828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
